Triple-negative and basal-like breast cancer:Implications for oncologists

Current Oncology

Volumn 18, Issue 4, 2011, Pages 161-164

  Lachapelle, J ^a   Foulkes, William D ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE DERIVATIVE; FLUOROURACIL; GEMCITABINE; INIPARIB; METHOTREXATE; OLAPARIB; PACLITAXEL;

BASAL LIKE BREAST CANCER; BODY MASS; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; EDITORIAL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MENARCHE; MOLECULARLY TARGETED THERAPY; ONCOGENE; PROGNOSIS; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 80051536989     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i4.824     Document Type: Editorial

References (27)

1. Soslash;rlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-7
2. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol 2009;18:125-32
3. Tischkowitz M, Brunet JS, Be,acute;gin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007;7:134
4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48
5. Rakha E, Reis-Filho JS. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med 2009;133:860-8
6. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triplenegative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010;7:683-92
7. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basallike breast cancer. Breast Cancer Res Treat 2008;109:123-39
8. Hamm C, El-Masri M, Poliquin G, et al. A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. Curr Oncol 2011;18:191-196
9. Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO. Tumor size is an unreliable predictor of prognosis in basallike breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat 2009;117:199-204
10. O'Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100-10
11. Enright K, Dent R. Treatment options for triple-negative breast cancer. Emerg Cancer Ther 2010;1:589-606
12. Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase iii trials evaluating the predictive value of her2 and topoisomerase ii alpha in early breast cancer patients treated with cmf or anthracycline-based adjuvant therapy [abstract 705]. Breast Cancer Res Treat 2008;107(suppl):24. [Available online at: www.abstracts2view.com/sabcs/view. php?nu=SABCS08L_538; cited June 21, 2011]
13. Cheang M, Chia SK, Tu D, et al. Anthracyclines in basal breast cancer: the ncic-ctg trial ma.5 comparing adjuvant cmf to cef [abstract 519]. J Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/ Abstracts?,vmview=abst_detail_view,conf ID=65,amp;abstractID=35150; cited June 15, 2011]
14. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81
15. Nahleh Z. Neoadjuvant chemotherapy for,quot;triple negative,quot; breast cancer: a review of current practice and future outlook. Med Oncol 2010;27:531-9
16. Ellis P,Barrett-Lee P., Johnson, et al. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (tact): an open-label, phase iii, randomised controlled trial. Lancet 2009;373:1681-92
17. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53
18. Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with brca1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9
19. Roché H, Conte P, Perez EA, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase iii studies. Breast Cancer Res Treat 2011;125:755-65
20. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010;7:718-24
21. Drew Y, Plummer R. The emerging potential of poly(adp-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol 2010;22:67-71
22. Sanofi-Aventis. Sanofi-Aventis Reports Top-Line Results from Phase iii Study with BSI-201 in Metastatic Triple-Negative Breast Cancer [press release]. Paris, France: Sanofi-Aventis; 2011. [Available online at: en.sanofi.com/binaries/20110127_ BSI_en_tcm28-30168.pdf; cited June 15, 2011]
23. Tutt A, Robson M, Garber JE, et al. Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44
24. Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to parp inhibitors? A phase ii correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract 3002]. J Clin Oncol 2010;28:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?,vmview=abst_detail_view,confID=74,abstractID=50240; cited June 15, 2011]
25. Sun T, Aceto N, Meerbrey KL, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the ptpn12 phosphatase. Cell 2011;144:703-18
26. Albeck JG, Brugge JS. Uncovering a tumor suppressor for triple-negative breast cancers. Cell 2011;144:638-40
27. Pakkiri P, Lakhani SR, Smart CE. Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology 2009;41:89-99